Drug intelligence / Profile preview

GEN-310

Development stage: Preclinical
Lead developer: GenVivo
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

GEN-310 is an investigational in vivo gene therapy developed by GenVivo for the treatment of B-cell malignancies. The therapy utilizes a viral vector platform designed to reprogram a patient's endogenous T cells and natural killer (NK) cells directly within the body to express chimeric antigen receptors (CARs). This in vivo approach aims to circumvent the logistical challenges, high costs, and lengthy manufacturing times associated with traditional ex vivo CAR-T cell production. By transforming immune cells in situ, GEN-310 seeks to generate a sustained therapeutic population of CAR-expressing cells to target and eliminate malignant B cells. As of late 2025, GEN-310 is in the IND-enabling and preclinical stages of development.

Beyond the preview

Go deeper on GEN-310.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GEN-310.

Explore the full profile